A recent Respiratory Medicine digest,
as sent to subscribers

Study Type: Retrospective observational study (doubly robust difference-in-differences analysis)

Key Question: Did NYCHA's citywide 'Mold Busters' remediation programme reduce asthma-related ED visits among public housing residents?

Key Findings:

• The intervention was associated with an average annual reduction of 7.2 asthma-related ED visits per 1,000 residents (95% CI: -9.6, -4.8), equating to ~2,200 fewer visits annually by 2022–2023 (19% lower than expected).
• Buildings with the largest reductions in mold reports saw visit rate reductions up to 12.0 per 1,000 residents (95% CI: -16.9, -7.0).
• Effects were stronger in adults than children and more pronounced in winter/spring; mold reports still rose after extreme precipitation events despite overall decline.

Clinical Relevance: Supports housing-based environmental interventions as a scalable public health strategy to reduce asthma exacerbations and health inequalities in disadvantaged populations, relevant to UK social housing and asthma disparity initiatives.

Limitations: Observational design using building-level (not individual-level) data limits causal inference and control for unmeasured confounders.

Study Type: Retrospective multicentre cohort analysis (international meta-registry)

Key Question: Do measures of pulmonary artery pulsatile load and RV-vascular coupling (arterial elastance [Ea], pulmonary artery compliance [PAC], stroke volume index [SVI]) predict mortality independently of PVR, particularly in mild pulmonary hypertension?

Key Findings:

• In mild PH (mPAP 20–25 mmHg, n=1,097), neither mPAP nor PVR predicted mortality (p>0.05), but Ea, PAC, SVI, and heart rate were independently prognostic.
• In the full cohort (n=16,899, PH groups 1–5), these pulsatile/RV-coupling parameters remained independently associated with survival after adjustment for confounders, including PVR/TPR.
• Findings were consistent across aetiological subgroups, including IPAH/heritable PAH.

Clinical Relevance: These integrated haemodynamic parameters could improve risk stratification in mild/early PH—a population increasingly identified in UK PH centres following revised diagnostic thresholds—where conventional steady-flow metrics (mPAP, PVR) lack prognostic discrimination.

Limitations: Retrospective registry design limits causal inference and may be affected by unmeasured confounding and variable data completeness across contributing centres.

Study Type: Multicenter retrospective cohort study

Key Question: What are the outcomes and independent prognostic factors for septic shock in allogeneic HSCT recipients admitted to ICU?

Key Findings:

• Septic shock affected 38% (444/1,164) of allo-HSCT ICU admissions; 90-day and 3-year mortality were 63% and 81% respectively.
• Fungal documentation (HR 1.78, 95% CI 1.19–2.67), higher SOFA score (HR 1.07 per point, 95% CI 1.02–1.13), and neutropenia (HR 3.94, 95% CI 1.18–13.1) independently predicted worse 90-day survival.
• Early aminoglycoside use was associated with improved survival (HR 0.46, 95% CI 0.33–0.64) but with a non-constant, time-varying effect, precluding causal inference.

Clinical Relevance: These findings highlight the extremely poor prognosis of septic shock post-allo-HSCT and support risk-stratification by illness severity, neutropenic status, and fungal aetiology when planning ICU-level care in UK transplant centres.

Limitations: Retrospective design limits causal interpretation, particularly regarding the aminoglycoside-survival association.

Study Type: Ecological/cross-sectional analysis using global health system databases (WHO, World Bank, DIRAC, UNDP, IARC).

Key Question: Which national health system factors are independently associated with lung cancer mortality-to-incidence ratios globally?

Key Findings:

• Higher health spending, nurse/midwife density, universal health coverage index, and radiotherapy centre density were each independently associated with lower lung cancer mortality-to-incidence ratios.
• Physician density showed a small, paradoxical positive association with mortality-to-incidence ratio after adjustment.
• No specific effect sizes or confidence intervals reported in the abstract.

Clinical Relevance: Highlights health system infrastructure (workforce composition, universal coverage, radiotherapy access) rather than physician numbers alone as key levers for improving lung cancer outcomes—relevant to NHS workforce and radiotherapy capacity planning amid rising lung cancer burden.

Limitations: Ecological, country-level data cannot establish causation or account for confounding at the individual patient level.

Study Type: Randomised, double-blind, placebo-controlled trial (n=68)

Key Question: Does gabapentin reduce chronic cough in patients with idiopathic pulmonary fibrosis (IPF)?

Key Findings:

• Cough relief rate (≥50% reduction in Cough Symptom Score) at 12 weeks was 73.5% with gabapentin vs 26.5% with placebo (absolute difference 47.1 percentage points, 95% CI 26.1–68.0, P<0.001).
• Adverse events were more frequent with gabapentin (32.4% vs 8.8%), mainly drowsiness, fatigue, and dizziness; no serious safety signals reported.

Clinical Relevance: Chronic cough in IPF has no established evidence-based pharmacological therapy, and this trial provides the first randomised evidence supporting gabapentin as an option for UK clinicians managing this difficult symptom, particularly in specialist ILD services where off-label neuromodulator use for cough is already common practice.

Limitations: Single-centre design with a small sample size limits generalisability and precision of safety estimates.

Study Type: Multicenter observational (diagnostic accuracy) study

Key Question: How well does the VExUS score predict invasively measured right atrial pressure (RAP) in patients with suspected or confirmed pulmonary hypertension?

Key Findings:

• Mean RAP rose progressively with VExUS grade (3.9 mmHg at grade 0 to 15.8 mmHg at grade 3; p<0.001).
• VExUS showed excellent discrimination for RAP >12 mmHg (AUC 0.97, 95% CI 0.94–0.99), outperforming isolated echocardiographic markers and matching composite echocardiographic RAP estimation.
• Findings were consistent across pre-capillary, post-capillary, and normal haemodynamic phenotypes.

Clinical Relevance: VExUS offers a validated, non-invasive bedside tool to estimate RAP in PH clinics, potentially reducing reliance on right heart catheterisation for congestion assessment in UK PH services.

Limitations: Cross-sectional design with modest subgroup sizes (particularly post-capillary and no-PH groups) limits generalisability and assessment of longitudinal utility.

Study Type: Commentary/editorial

Key Question: Does erdosteine, a muco-active agent, have a role in preventing mucus plug formation and associated exacerbations in early COPD?

Key Findings:

• Mucus plugging is highlighted as a key driver of clinical deterioration in COPD.
• Erdosteine is proposed to reduce exacerbation frequency when used early in disease course.
• The abstract suggests a potential (not yet confirmed) effect of erdosteine in slowing mucus plug development, without providing quantitative data.

Clinical Relevance: For NHS respiratory clinicians managing early COPD, mucoactive therapy could represent an accessible, low-cost adjunct to reduce exacerbation burden, pending confirmatory evidence.

Limitations: As an editorial/commentary, this piece offers no original trial data or effect sizes to substantiate the proposed mechanism or clinical benefit.

Study Type: Narrative review

Key Question: How does inflammation interact with fibrotic pathways across fibrotic interstitial lung diseases (fILDs), and what are the implications for treatment stratification?

Key Findings:

• Inflammation and fibrosis are not sequential but dynamically interlinked, forming feed-forward loops that can either propagate or, in some contexts, aid resolution of fibrosis.
• IPF is characterised by dominant fibrosis with limited inflammation, whereas other fILDs show variable, disease- and phenotype-dependent inflammatory contributions.
• Shared signalling pathways between inflammation and fibrosis underpin disease heterogeneity, supporting a rationale for mechanism-based rather than diagnosis-based treatment selection.

Clinical Relevance: For UK ILD services managing an increasingly diverse fILD caseload, understanding inflammation–fibrosis crosstalk supports more rational use of anti-fibrotic versus immunomodulatory therapies and informs future biomarker-driven stratification.

Limitations: As a narrative review, evidence is synthesised from experimental and translational studies rather than systematically appraised clinical trial data.